CRISPR Gene Editing Newsletter
Issue #11November 17, 20257 studies

CRISPR moves beyond rare blood diseases: first-of-its-kind human trial safely targets a cholesterol-regulating gene

CRISPR moves beyond rare blood diseases: first-of-its-kind human trial safely targets a cholesterol-regulating gene

Monday, November 17th CRISPR Gene Editing Newsletter Issue #11

CRISPR just reached a new milestone in human medicine. For the first time, scientists have safely used gene editing to turn off a cholesterol-regulating gene in peopleβ€”a step that moves the technology beyond rare genetic disorders toward treating common diseases like heart disease.

🎯 Phase 1 Trial Marks First Human Test of CRISPR on a Cholesterol Gene

The first human trial of CRISPR gene editing for cholesterol just delivered promising results. Researchers tested CTX310, which uses CRISPR to disable the ANGPTL3 gene in the liver (this gene normally blocks enzymes that break down cholesterol).

  • 15 participants with stubborn high cholesterol got a single IV dose, with the highest doses reducing ANGPTL3 protein levels by 73-80%

  • No serious side effects were linked to the treatment - one person died 179 days later from an unrelated sudden death, and another had a spinal disk issue

  • Only mild reactions occurred: 3 people (20%) had infusion reactions, and 1 person had temporary liver enzyme elevation that resolved in 2 weeks

Why it matters: For the first time, CRISPR has been used to safely switch off a cholesterol-raising gene in humansβ€”a step beyond treating rare genetic diseases. The approach mimics naturally protective mutations that keep cholesterol and triglycerides low, hinting at a future where heart disease prevention could come from a one-time edit, not daily pills.

πŸ† Top 0.1% journal πŸ”— New England Journal of Medicine πŸ—“οΈ Nov 10

Key Findings

🧬 Magnetic Nanorobots Boost Gene Editing Efficiency

Scientists created tiny magnetic robots (200 nanometers) that can actively move CRISPR components through cells. These "MagCbots" spin at high speeds when exposed to magnetic fields, reaching velocities of 0.41 micrometers per second inside cells. The spinning motion reduced cellular thickness by 50% and tripled the escape rate from cellular compartments that normally trap and destroy genetic material.

πŸ’‘ Active delivery systems could solve one of gene therapy's biggest challenges - getting treatments to the right place inside cells.
πŸŽ–οΈ Top 10% journal πŸ”— ACS Applied Materials and Interfaces πŸ—“οΈ Nov 4

πŸ”¬ Prime Editing Fixes Heart Disease Mutation

Researchers used prime editing (a newer, more precise form of gene editing) to correct a heart muscle disease mutation in human heart cells grown from stem cells. They achieved 34.8% editing efficiency in correcting the RBM20-P633L mutation that causes dilated cardiomyopathy. The editing restored normal protein location and fixed abnormal splicing of heart-related genes.

πŸ’‘ Prime editing may offer a path to treat inherited heart diseases by directly fixing the genetic typos that cause them.
πŸ₯‰ Top 5% journal πŸ”— Molecular Therapy Nucleic Acids πŸ—“οΈ Nov 10

🎯 New RNA Editing System Lowers Cholesterol in Mice

Scientists developed "ProAPOBECs" - enhanced RNA editing tools that can modify genetic messages without permanently changing DNA. When they used these tools to edit Pcsk9 RNA in mouse livers (a gene that regulates cholesterol), it effectively lowered cholesterol levels. They also tested it in an autism mouse model, where editing Mef2c RNA significantly improved disease symptoms.

πŸ’‘ RNA editing could provide temporary genetic fixes for diseases, offering benefits without permanent DNA changes.
πŸ₯ˆ Top 2% journal πŸ”— Nature Communications πŸ—“οΈ Nov 4

πŸ§ͺ Anti-CRISPR Proteins Enable Precise Control

Researchers solved a major CRISPR problem in bacteria by combining the gene editing system with "anti-CRISPR" proteins that can turn it on and off. Using the AcrIIA4 protein from Listeria, they successfully edited genes in the notoriously difficult-to-modify bacterium Clostridium beijerinckii. The system allowed multiple rounds of editing while preventing the toxicity that usually kills bacterial cells during CRISPR experiments.

πŸ’‘ Controllable CRISPR systems could unlock gene editing in bacterial species that have been impossible to modify.
Top 30% journal πŸ”— Journal of Biotechnology πŸ—“οΈ Nov 7

πŸ”¬ CRISPR Targets Cancer's Fusion Genes

Scientists used CRISPR to disrupt BRD4::NUTM1, an abnormal fusion gene that drives NUT carcinoma, a highly aggressive cancer with no established treatments. Multiple guide RNAs successfully broke apart the fusion gene at the DNA level, eliminating the cancer-driving protein. This led to significant reductions in cancer cell growth, cell cycle arrest, and increased cell death.

πŸ’‘ CRISPR could provide precision treatments for cancers driven by specific genetic fusions.
πŸŽ–οΈ Top 10% journal πŸ”— Molecular Therapy Oncology πŸ—“οΈ Nov 5

πŸ“Š Eleven Testis Genes Prove Unnecessary for Male Fertility

Two separate studies knocked out 17 different genes that are highly active in testicles to see which ones are essential for male fertility. Surprisingly, mice lacking any of these 17 genes maintained completely normal fertility, testis appearance, sperm quality, and reproductive success in mating tests. This included genes like Efcab7, Tekt3, and others previously thought to be important for reproduction.

πŸ’‘ Male fertility may be more genetically robust than expected, with extensive backup systems protecting reproductive function.
Top 20% journal πŸ”— Andrology πŸ—“οΈ Nov 10

Implications

This week's research shows CRISPR moving from lab curiosity to real medical treatments, with the first human cholesterol trial proving safety and efficacy. Meanwhile, new delivery methods and control systems are solving the technical challenges that have limited gene editing's reach, potentially opening doors to treating everything from muscle diseases to cancer.

Studies in this issue

Primary sources used for this newsletter.

  1. Early Human Trial of Gene Editing Targeting ANGPTL3
    main storyThe New England journal of medicine2025-11-10PMID 41211945
  2. Magnetic fast-moving tiny particle groups to improve CRISPR/Cas9 gene editing
    key findingACS applied materials & interfaces2025-11-04PMID 41185939
  3. Prime editing fixes heart muscle disease caused by RBM20-P633L mutation in human heart cells
    key findingMolecular therapy. Nucleic acids2025-11-10PMID 41210585
  4. Using CRISPR-Cas9 gene editing to target cancer caused by fusion genes in NUT carcinoma
    key findingMolecular therapy. Oncology2025-11-05PMID 41190236
  5. Using CRISPR and anti-CRISPR tools to edit the DNA of Clostridium beijerinckii bacteria
    key findingJournal of biotechnology2025-11-07PMID 41202983